API | volitinib

volitinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
None

More Chemistry

Pharmacology

Mechanism of Action:
- Hepatocyte growth factor receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 3)

Colorectal Neoplasms (Phase 1)

Enzyme Inhibitors (Phase 3)

Health (Phase 1)

Kidney Diseases (Phase 3)

Kidney Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 1)

Neoplasms by Site (Phase 3)

Pharmacology (Phase 1)

Protein Kinase Inhibitors (Phase 3)

Stomach Neoplasms (Phase 2)

Urologic Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 15
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue